Cargando…

Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review

Pancreatic adenocarcinoma is one of the deadliest types of cancer worldwide, with a 5-year survival rate of 8% despite recent treatment advancements. The present systematic review aimed to investigate the role of hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical resection for panc...

Descripción completa

Detalles Bibliográficos
Autores principales: Larentzakis, Andreas, Anagnostou, Evangelos, Georgiou, Konstantinos, Vrakopoulou, Gavriella-Zoi, Zografos, Constantinos G., Zografos, Georgios C., Toutouzas, Konstantinos G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882886/
https://www.ncbi.nlm.nih.gov/pubmed/33664810
http://dx.doi.org/10.3892/ol.2021.12507
_version_ 1783651140832854016
author Larentzakis, Andreas
Anagnostou, Evangelos
Georgiou, Konstantinos
Vrakopoulou, Gavriella-Zoi
Zografos, Constantinos G.
Zografos, Georgios C.
Toutouzas, Konstantinos G.
author_facet Larentzakis, Andreas
Anagnostou, Evangelos
Georgiou, Konstantinos
Vrakopoulou, Gavriella-Zoi
Zografos, Constantinos G.
Zografos, Georgios C.
Toutouzas, Konstantinos G.
author_sort Larentzakis, Andreas
collection PubMed
description Pancreatic adenocarcinoma is one of the deadliest types of cancer worldwide, with a 5-year survival rate of 8% despite recent treatment advancements. The present systematic review aimed to investigate the role of hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical resection for pancreatic adenocarcinoma, with or without peritoneal carcinomatosis. A systematic search of the MEDLINE and SCOPUS electronic databases was performed according to PRISMA guidelines. All possible relevant articles published between January 1980 and May 2019 were retrieved using multiple search terms associated with HIPEC and pancreatic adenocarcinoma. The initial search resulted in 1,244 reports, which condensed to 41 reports following screening of titles and abstracts, and subsequently to four reports following full-text thorough examination. The four reports included involved a prospective cohort study of HIPEC use in resectable pancreatic adenocarcinoma, and three retrospective studies of HIPEC use following cytoreductive surgery for peritoneal carcinomatosis due to pancreatic adenocarcinoma, resulting in a total of 47 patients. The overall survival ranged between 2 and 62 months, and the hospital mortality rate was 8.5%. Morbidity (34%) was mainly attributed to anastomotic leak or respiratory failure. Due to the small sample size and low quality of evidence of the included studies, no valid conclusions could be drawn. Therefore, further studies are required to justify the use of HIPEC as an adjuvant therapy in resectable pancreatic adenocarcinoma, while cytoreductive surgery and HIPEC in peritoneal carcinomatosis of pancreatic origin seems not only not useful but also unsafe at this level of evidence.
format Online
Article
Text
id pubmed-7882886
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-78828862021-03-03 Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review Larentzakis, Andreas Anagnostou, Evangelos Georgiou, Konstantinos Vrakopoulou, Gavriella-Zoi Zografos, Constantinos G. Zografos, Georgios C. Toutouzas, Konstantinos G. Oncol Lett Articles Pancreatic adenocarcinoma is one of the deadliest types of cancer worldwide, with a 5-year survival rate of 8% despite recent treatment advancements. The present systematic review aimed to investigate the role of hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical resection for pancreatic adenocarcinoma, with or without peritoneal carcinomatosis. A systematic search of the MEDLINE and SCOPUS electronic databases was performed according to PRISMA guidelines. All possible relevant articles published between January 1980 and May 2019 were retrieved using multiple search terms associated with HIPEC and pancreatic adenocarcinoma. The initial search resulted in 1,244 reports, which condensed to 41 reports following screening of titles and abstracts, and subsequently to four reports following full-text thorough examination. The four reports included involved a prospective cohort study of HIPEC use in resectable pancreatic adenocarcinoma, and three retrospective studies of HIPEC use following cytoreductive surgery for peritoneal carcinomatosis due to pancreatic adenocarcinoma, resulting in a total of 47 patients. The overall survival ranged between 2 and 62 months, and the hospital mortality rate was 8.5%. Morbidity (34%) was mainly attributed to anastomotic leak or respiratory failure. Due to the small sample size and low quality of evidence of the included studies, no valid conclusions could be drawn. Therefore, further studies are required to justify the use of HIPEC as an adjuvant therapy in resectable pancreatic adenocarcinoma, while cytoreductive surgery and HIPEC in peritoneal carcinomatosis of pancreatic origin seems not only not useful but also unsafe at this level of evidence. D.A. Spandidos 2021-04 2021-02-03 /pmc/articles/PMC7882886/ /pubmed/33664810 http://dx.doi.org/10.3892/ol.2021.12507 Text en Copyright: © Larentzakis et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Larentzakis, Andreas
Anagnostou, Evangelos
Georgiou, Konstantinos
Vrakopoulou, Gavriella-Zoi
Zografos, Constantinos G.
Zografos, Georgios C.
Toutouzas, Konstantinos G.
Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review
title Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review
title_full Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review
title_fullStr Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review
title_full_unstemmed Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review
title_short Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review
title_sort place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: a survival, mortality and morbidity systematic review
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882886/
https://www.ncbi.nlm.nih.gov/pubmed/33664810
http://dx.doi.org/10.3892/ol.2021.12507
work_keys_str_mv AT larentzakisandreas placeofhyperthermicintraperitonealchemotherapyinthearmamentagainstpancreaticadenocarcinomaasurvivalmortalityandmorbiditysystematicreview
AT anagnostouevangelos placeofhyperthermicintraperitonealchemotherapyinthearmamentagainstpancreaticadenocarcinomaasurvivalmortalityandmorbiditysystematicreview
AT georgioukonstantinos placeofhyperthermicintraperitonealchemotherapyinthearmamentagainstpancreaticadenocarcinomaasurvivalmortalityandmorbiditysystematicreview
AT vrakopoulougavriellazoi placeofhyperthermicintraperitonealchemotherapyinthearmamentagainstpancreaticadenocarcinomaasurvivalmortalityandmorbiditysystematicreview
AT zografosconstantinosg placeofhyperthermicintraperitonealchemotherapyinthearmamentagainstpancreaticadenocarcinomaasurvivalmortalityandmorbiditysystematicreview
AT zografosgeorgiosc placeofhyperthermicintraperitonealchemotherapyinthearmamentagainstpancreaticadenocarcinomaasurvivalmortalityandmorbiditysystematicreview
AT toutouzaskonstantinosg placeofhyperthermicintraperitonealchemotherapyinthearmamentagainstpancreaticadenocarcinomaasurvivalmortalityandmorbiditysystematicreview